Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2010-07-22

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm100139bPMID 20575550PMCID PMC4289617
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dynamic association of MLL1, H3K4 trimethylation with chromatin and Hox gene expression during the cell cycle

  2009cited by this paper
• WDR5, a complexed protein

  2009cited by this paper
• On the Mechanism of Multiple Lysine Methylation by the Human Mixed Lineage Leukemia Protein-1 (MLL1) Core Complex*♦

  2009cited by this paper
• HOXA9 is required for survival in human MLL-rearranged acute leukemias.

  2009cited by this paper
• A Conserved Arginine-containing Motif Crucial for the Assembly and Enzymatic Activity of the Mixed Lineage Leukemia Protein-1 Core Complex*

  2008cited by this paper
• WDR5 Interacts with Mixed Lineage Leukemia (MLL) Protein via the Histone H3-binding Pocket*

  2008cited by this paper
• Chromosomal rearrangements leading to MLL gene fusions: clinical and biological aspects.

  2008cited by this paper
• Structure of WDR5 Bound to Mixed Lineage Leukemia Protein-1 Peptide*

  2008cited by this paper
• Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation.

  2008cited by this paper
• Chromatin modifications and their function.

  2007cited by this paper
• Hox genes in hematopoiesis and leukemogenesis

  2007cited by this paper
• Downstream of Homeotic Genes: In the Heart of Hox function

  2007cited by this paper
• Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors.

  2007cited by this paper
• Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex

  2006cited by this paper
• Structural basis for the specific recognition of methylated histone H3 lysine 4 by the WD-40 protein WDR5.

  2006cited by this paper
• Structural basis for molecular recognition and presentation of histone H3 By WDR5

  2006cited by this paper
• Histone H3 Lys 4 methylation: caught in a bind?

  2006cited by this paper
• Regulation of MLL1 H3K4 methyltransferase activity by its core components

  2006cited by this paper
• A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling

  2006cited by this paper
• Molecular recognition of histone H3 by the WD40 protein WDR5

  2006cited by this paper
• WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development.

  2005cited by this paper
• Global and Hox-specific roles for the MLL1 methyltransferase.

  2005cited by this paper
• Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization.

  2004cited by this paper
• MLL: a histone methyltransferase disrupted in leukemia.

  2004cited by this paper
• Beyond homeosis--HOX function in morphogenesis and organogenesis.

  2003cited by this paper
• Proteolytic Cleavage of MLL Generates a Complex of N- and C-Terminal Fragments That Confers Protein Stability and Subnuclear Localization

  2003cited by this paper
• Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation.

  2003cited by this paper
• MLL3, a new human member of the TRX/MLL gene family, maps to 7q36, a chromosome region frequently deleted in myeloid leukaemia.

  2002cited by this paper
• Overexpression of the homeobox gene HOXC8 in human prostate cancer correlates with loss of tumor differentiation *

  2002cited by this paper
• Translating the Histone Code

  2001cited by this paper
• MLL2, the second human homolog of the Drosophila trithorax gene, maps to 19q13.1 and is amplified in solid tumor cell lines

  1999cited by this paper
• The oncogenic potential of deregulated homeobox genes.

  1993cited by this paper
• Expression of homeobox-containing genes in primary and metastatic colorectal cancer.

  1993cited by this paper

• Peptide-based inhibitors of epigenetic proteins.

  2025cites this paper
• Therapeutic targeting of WDR5-MLL1 by EMBOW-derived peptides suppresses leukemia progression.

  2025cites this paper
• Chromatin Regulatory Targets for Anticancer Therapeutics.

  2025cites this paper
• Exploring the Potential of Pyridine Carboxylic Acid Isomers to Discover New Enzyme Inhibitors

  2025cites this paper
• The neural stem cell gene PAFAH1B1 controls cell cycle progression, DNA integrity, and paclitaxel sensitivity of triple-negative breast cancer cells

  2025cites this paper
• A virtual library of small molecules mimicking dipeptides

  2024cites this paper
• WDR5 Binding to Histone Serotonylation Is Driven by an Edge-Face Aromatic Interaction with Unexpected Electrostatic Effects.

  2024cites this paper
• Expanded profiling of WD repeat domain 5 inhibitors reveals actionable strategies for the treatment of hematologic malignancies

  2024cites this paper
• Chemical inhibitors targeting histone methylation readers.

  2024cites this paper
• Small molecule WDR5 inhibitors down-regulate lncRNA expression

  2024cites this paper
• Structure-Based Discovery of Potent, Orally Bioavailable Benzoxazepinone-Based WD Repeat Domain 5 Inhibitors.

  2023cites this paper
• Macrocyclic peptides as inhibitors of WDR5-lncRNA interactions.

  2023cites this paper
• Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models

  2022influential citation
• Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-Based Optimization.

  2022cites this paper
• Impact of WIN site inhibitor on the WDR5 interactome

  2021cites this paper
• Lysine methyltransferase inhibitors: where we are now

  2021cites this paper
• MEIS1 in Hematopoiesis and Cancer. How MEIS1-PBX Interaction Can Be Used in Therapy

  2021cites this paper
• Histone Methylation Related Therapeutic Challenge in Cardiovascular Diseases

  2021cites this paper
• Targeting WD Repeat-Containing Protein 5 (WDR5): A Medicinal Chemistry Perspective.

  2021cites this paper
• Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity.

  2021cites this paper
• Discovery of DDO-2213 as a Potent and Orally Bioavailable Inhibitor of the WDR5-Mixed Lineage Leukemia 1 Protein-Protein Interaction for the Treatment of MLL Fusion Leukemia.

  2021cites this paper
• Kinetics of the multitasking high-affinity Win binding site of WDR5 in restricted and unrestricted conditions.

  2021cites this paper
• Structure, function and inhibition of critical protein–protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins

  2021cites this paper
• Discovery and Structure-Based optimization of potent and selective WDR5 inhibitors containing a dihydroisoquinolinone bicyclic core

  2020cites this paper
• SET1/MLL family of proteins: functions beyond histone methylation

  2020cites this paper
• Targeting epigenetic protein-protein interactions with small-molecule inhibitors.

  2020cites this paper
• Targeting Protein–Protein Interactions Perspective

  2020cites this paper
• The development of inhibitors targeting the Mixed lineage leukemia 1 (MLL1)-WD repeat domain 5 protein (WDR5) Protein-Protein Interaction.

  2019cites this paper
• Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity

  2019cites this paper
• Expression of WD Repeat Domain 5 (WDR5) is Associated with Progression and Reduced Prognosis in Papillary Thyroid Carcinoma

  2019cites this paper
• Direct and Indirect Targeting of HOXA9 Transcription Factor in Acute Myeloid Leukemia

  2019cites this paper
• Photoswitchable peptides for spatiotemporal control of biological functions.

  2019cites this paper
• Targeting epigenetic machinery: Emerging novel allosteric inhibitors.

  2019cites this paper
• Discovery and Structure-Based Optimization of Potent and Selective WD repeat domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core.

  2019cites this paper
• Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.

  2019cites this paper
• Methyl-Readers and Inhibitors

  2019cites this paper
• Targeting protein-protein interaction between MLL1 and reciprocal proteins for leukemia therapy.

  2018cites this paper
• Moonlighting with WDR5: A Cellular Multitasker

  2018cites this paper
• Functional Signature Ontology-Based Identification and Validation of Novel Therapeutic Targets and Natural Products for the Treatment of Cancer

  2018cites this paper
• Development of novel PROTAC Small-Molecule Degraders of MDM2 Protein and Peptidomimetic Inhibitors Targeting WDR5-MLL1 Protein-Protein Interaction

  2018cites this paper
• Discovery of Potent 2-Aryl-6,7-dihydro-5 H-pyrrolo[1,2- a]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design.

  2018cites this paper
• Rational design and screening of peptide-based inhibitors of heat shock factor 1 (HSF1).

  2018cites this paper
• Implications of Epigenetic Mechanisms and their Targets in Cerebral Ischemia Models

  2017cites this paper
• Controlled inhibition of methyltransferases using photoswitchable peptidomimetics: towards an epigenetic regulation of leukemia† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc00137a Click here for additional data file.

  2017cites this paper
• Approaches to target WD40 proteins and synthesis and evaluation of chemical tools for on-bead screening

  2017cites this paper
• An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.

  2017cites this paper
• Mixed-Lineage Leukemia Fusions and Chromatin in Leukemia.

  2017cites this paper
• Targeting human SET1/MLL family of proteins

  2017influential citation
• Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction.

  2017cites this paper
• Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction.

  2016cites this paper
• Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes*

  2016cites this paper
• High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.

  2016cites this paper
• Identification of a small-molecule ligand of the epigenetic reader protein Spindlin1 via a versatile screening platform

  2016cites this paper
• Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5.

  2016cites this paper
• Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1).

  2016cites this paper
• Interplay between p53 and epigenetic pathways in cancer

  2016cites this paper
• Targeting protein–protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies?

  2015cites this paper
• Development and Use of Assay Conditions Suited to Screening for and Profiling of SET-Domain-Targeted Inhibitors of the MLL/SET1 Family of Lysine Methyltransferases

  2015cites this paper
• Hijacked in cancer: the KMT2 (MLL) family of methyltransferases

  2015cites this paper
• Prevalent p53 mutants co-opt chromatin pathways to drive cancer growth

  2015cites this paper
• Disturbing the histone code in leukemia: translocations and mutations affecting histone methyl transferases.

  2015cites this paper
• Structure-based design of conformationally constrained cyclic peptidomimetics to target the MLL1-WDR5 protein–protein interaction as inhibitors of the MLL1 methyltransferase activity

  2015cites this paper
• Updated research and applications of small molecule inhibitors of Keap1-Nrf2 protein-protein interaction: a review.

  2014cites this paper
• Thermodynamic and structural characterization of the interaction between WD-40 repeat protein 5 (WDR5) and human SET1 family methyltransferases

  2013cites this paper
• High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction.

  2013cites this paper
• ATX1-Generated H3K4me3 Is Required for Efficient Elongation of Transcription, Not Initiation, at ATX1-Regulated Genes

  2012cites this paper
• Generating Peptide Probes against Cancer-related Peptide Recognition Domains using Phage Display

  2012cites this paper
• Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis

  2012cites this paper
• Structural Basis for WDR5 Interaction (Win) Motif Recognition in Human SET1 Family Histone Methyltransferases*

  2012cites this paper
• Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5

  2012cites this paper
• Structural and Functional Dissection of the MLL1 Histone Methyltransferase Complex

  2011cites this paper
• Chromatin-Modifying Agents for Epigenetic Reprogramming and Endogenous Neural Stem Cell-Mediated Repair in Stroke

  2011influential citation
• Biochemistry of the Mixed Lineage Leukemia 1 (MLL1) Protein and Targeted Therapies for Associated Leukemia

  2011influential citation
• Fine‐tuning the stimulation of MLL1 methyltransferase activity by a histone H3‐based peptide mimetic

  2010influential citation